Telomir Pharma’s latest funding round of $3 million through equity financing aims to support its Rare Disease Investigational New Drug (IND) development. Telomir-1, the company’s lead candidate, has shown promising results in preclinical models, including reversing the biological clock, enhancing lifespan and health span, improving mitochondrial energy production, reducing oxidative stress, correcting calcium signaling pathways […]